Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload

被引:17
|
作者
Li, Wei-ming [1 ]
Zhao, Yi-fan [1 ]
Zhu, Guo-fu [1 ]
Peng, Wen-hui [1 ]
Zhu, Meng-yun [1 ]
Yu, Xue-jing [1 ]
Chen, Wei [1 ]
Xu, Da-chun [1 ]
Xu, Ya-wei [1 ]
机构
[1] Tongji Univ, Shanghai Peoples Hosp 10, Dept Cardiol, Sch Med, Shanghai 200072, Peoples R China
基金
中国国家自然科学基金;
关键词
cardiac hypertrophy; dual specific phosphatase 12; c-Jun N-terminal kinase (JNK); signalling pathway; SP600125; N-TERMINAL KINASE; HEART-FAILURE; ACTIVATION; REGULATORS; CARDIOMYOPATHY; IDENTIFICATION; APOPTOSIS; REVEALS; BINDING; ERK1/2;
D O I
10.1042/CS20160664
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pathological cardiac hypertrophy is an independent risk factor of heart failure. However, we still lack effective methods to reverse cardiac hypertrophy. DUSP12 is a member of the dual specific phosphatase (DUSP) family, which is characterized by its DUSP activity to dephosphorylate both tyrosine and serine/threonine residues on one substrate. Some DUSPs have been identified as being involved in the regulation of cardiac hypertrophy. However, the role of DUSP12 during pathological cardiac hypertrophy is still unclear. In the present study, we observed a significant decrease in DUSP12 expression in hypertrophic hearts and cardiomyocytes. Using a genetic loss-of-function murine model, we demonstrated that DUSP12 deficiency apparently aggravated pressure overload-induced cardiac hypertrophy and fibrosis as well as impaired cardiac function, whereas cardiac-specific overexpression of DUPS12 was capable of reversing this hypertrophic and fibrotic phenotype and improving contractile function. Furthermore, we demonstrated that JNK1/2 activity but neither ERK1/2 nor p38 activity was increased in the DUSP12 deficient group and decreased in the DUSP12 overexpression group both in vitro and in vivo under hypertrophic stress conditions. Pharmacological inhibition of JNK1/2 activity (SP600125) is capable of reversing the hypertrophic phenotype in DUSP12 knockout (KO) mice. DUSP12 protects against pathological cardiac hypertrophy and related pathologies. This regulatory role of DUSP12 is primarily through c-Jun N-terminal kinase (JNK) inhibition. DUSP12 could be a promising therapeutic target of pathological cardiac hypertrophy. DUSP12 is down-regulated in hypertrophic hearts. An absence of DUSP12 aggravated cardiac hypertrophy, whereas cardiomyocyte-specific DUSP12 overexpression can alleviate this hypertrophic phenotype with improved cardiac function. Further study demonstrated that DUSP12 inhibited JNK activity to attenuate pathological cardiac hypertrophy.
引用
收藏
页码:141 / 154
页数:14
相关论文
共 50 条
  • [31] Effects of enalapril in rats with pressure overload cardiac hypertrophy
    Eugenio, DD
    Pietro, G
    Rosario, M
    DeSarro, G
    GENERAL PHARMACOLOGY, 1997, 28 (04): : 531 - 533
  • [32] MECHANISM FOR CARDIAC-HYPERTROPHY BY AORTIC PRESSURE OVERLOAD
    KIRA, Y
    KOCHEL, P
    MORGAN, HE
    FEDERATION PROCEEDINGS, 1983, 42 (05) : 1257 - 1257
  • [33] Kaempherol attenuated cardiac hypertrophy induced by pressure overload
    Hong, Feng
    Cao, Jianglei
    Zhang, Guangyu
    Feng, Hong
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (16) : C14 - C14
  • [34] BM-derived cells contribute to the pathogenesis of cardiac hypertrophy in response to pressure overload
    Endo, Jin
    Sano, Motoaki
    Fujita, Jun
    Hayashida, Kentaro
    Ogawa, Satoshi
    Fukuda, Keiichi
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2006, 41 (06) : 1047 - 1047
  • [35] Effects of a high saturated fat diet on cardiac hypertrophy and dysfunction in response to pressure overload
    Chess, David J.
    Lei, Biao
    Hoit, Brian D.
    Azimzadeh, Agnes M.
    Stanley, William C.
    JOURNAL OF CARDIAC FAILURE, 2008, 14 (01) : 82 - 88
  • [36] Caspase Recruitment Domain 6 Protects Against Cardiac Hypertrophy in Response to Pressure Overload
    Li, Liangpeng
    Chen, Wen
    Zhu, Yifan
    Wang, Xiaodi
    Jiang, Ding-Sheng
    Huang, Fuhua
    Wang, Liming
    Xiang, Fei
    Qin, Wei
    Wang, Qiang
    Zhang, Rui
    Zhu, Xueyong
    Li, Hongliang
    Chen, Xin
    HYPERTENSION, 2014, 64 (01) : 94 - 102
  • [37] YAP mediates compensatory cardiac hypertrophy through aerobic glycolysis in response to pressure overload
    Kashihara, Toshihide
    Mukai, Risa
    Oka, Shin-ichi
    Zhai, Peiyong
    Nakada, Yasuki
    Yang, Zhi
    Mizushima, Wataru
    Nakahara, Tsutomu
    Warren, Junco S.
    Abdellatif, Maha
    Sadoshima, Junichi
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (06):
  • [38] Augmented Cardiac Hypertrophy in Response to Pressure Overload in Mice Lacking ELTD1
    Xiao, Jinfeng
    Jiang, Hong
    Zhang, Rui
    Fan, Guangpu
    Zhang, Yan
    Jiang, Dingsheng
    Li, Hongliang
    PLOS ONE, 2012, 7 (05):
  • [39] Deletion of PPARα results in more pronounced cardiac hypertrophy in response to chronic pressure overload
    Smeets, Pascal J. H.
    Willemsen, Peter H.
    Brouns, Agnieszka E.
    Janssen, Ben J.
    van der Vusse, Ger J.
    van Bilsen, Marc
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2007, 42 : S130 - S130
  • [40] Lack of eNOS ameliorates left ventricular hypertrophy induced by pressure overload
    Takimoto, E
    Ren, SX
    Wang, YB
    Kass, DA
    CIRCULATION, 2003, 108 (17) : 238 - 238